StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Discrete and related tax charges (benefits) by Quarter

Discrete and related tax charges (benefits) ($M) ($M)

QuarterlyAnnual

Gilead Sciences Discrete and related tax charges (benefits): $44M in Q2 2026, down 191.7% from a year earlier.

Latest, Q2 2026
44
Period ended Jun 30, 2026
Change on a year earlier
-191.7%
-48 in Q2 2025
History
28 quarters
Since Q4 2018
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Discrete and related tax charges (4) | 44 | (48) | (2) | (90)”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗

Reported in Form 8-K GAAP to Non-GAAP Reconciliation.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDiscrete and related tax charges (benefits) ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202644-191.7%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026-46+9.5%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 2025454+1,465.5%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 2025-11-103.5%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 2025-48-20.0%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025-42+7.7%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 202429-341.7%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2024Sep 30, 2024314-641.4%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 2024-60-73.6%Form 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 2024-39+34.5%Form 8-K (exhibit991earningspressrel.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 2023-12-121.1%Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2023Sep 30, 2023-58-218.4%Form 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 2023-227-832.3%Form 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 2023-29-176.3%Form 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 202257-35.2%Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
Q3 2022Sep 30, 202249-70.3%Form 8-K (exhibit991earningspressrel.htm, filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences Discrete and related tax charges (benefits) ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng-adj-discrete-tax

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.